We found that the depletion of CXCL16 with an anti-CXCL16 neutralizing antibody attenuated leukemia progression and decreased the frequency of Th17 cells in the leukemia niche in vivo, suggesting that IL-17A mediates leukemia progression by promoting CXCL16 secretion. This evidence concerns the gene IL17A and leukemia.